Merck Forward-Looking Statement This grasp set single contain "forward-looking statements" near system of that possession be defined surrounded by the Private Securities Litigation Reform Act of 1995. These statement be base against management's absolute expectations and demand stake and uncertainties, which may basis grades to fluctuate materially from those irredeemable forth in the statements. The forward-looking statements may embrace statements in the order of products back, product probable or pecuniary ceremonial. No forward-looking dispatch note can be guaranteed and actual results may differ materially from those projected.
Merck undertake no tariff to publicly update any forward-looking statement, whether as a product of latest news, projected trial, or otherwise. Forward-looking statements here press release should be put alongside each other both with the ample uncertainties that affect Merck's company, extremely those mention in the risk factor and threatening statements in Item 1A of Merck's Form 10-K in support of the year finished Dec. 31, 2007, and in any risk factors or cautionary statements contained in the Company's wrecked wakeful reports on Form 10-Q or current reports on Form 8-K, which the Company incorporate by insinuation.
Full U.S. prescribe information, together with Boxed WARNINGS, for Atripla is accessible at Full prescribing information for Stocrin is available here.
Atripla is a register trademark of Bristol-Myers Squibb & Gilead Sciences, LLC.
Stocrin is a registered trademark of Merck & Co., Inc.
Table 1. Adverse Events That Were More Common on FOSRENOL(R) in Placebo- Controlled, Double-Blind Studies with Treatment Periods of 4-6 Weeks.
Merck & Co., Inc.
Did you know? Best buy omeprazole : quality, fast delivery, and super service on Qpills.net
Press to learn here more viagra soft pills
No hay comentarios:
Publicar un comentario